Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verve Therapeutics Inc VERV

Healthcare Biotechnology
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering... see more

Recent & Breaking News (NDAQ:VERV)

INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Verve Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Accesswire November 20, 2023

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Verve Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Accesswire November 17, 2023

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Verve Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Accesswire November 15, 2023

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Verve Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile November 13, 2023

Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia

GlobeNewswire November 12, 2023

Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

GlobeNewswire November 7, 2023

Verve and Lilly Relationship Expands to Include Verve's In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3

GlobeNewswire October 31, 2023

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia

GlobeNewswire October 23, 2023

Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association's Scientific Sessions 2023

GlobeNewswire September 26, 2023

Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

GlobeNewswire September 21, 2023

Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer

GlobeNewswire September 18, 2023

Verve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial Results

GlobeNewswire August 10, 2023

Verve Therapeutics to Present at the Canaccord 43rd Annual Growth Conference

GlobeNewswire August 3, 2023

Verve Establishes Global Collaboration with Lilly to Advance Verve's In Vivo Gene Editing Program Targeting Lp(a) for the Treatment of Atherosclerotic Cardiovascular Disease

GlobeNewswire June 15, 2023

Verve Therapeutics to Participate in the 2023 Jefferies Healthcare Conference

GlobeNewswire June 1, 2023

Verve Therapeutics to Participate in the Stifel 2023 Tailoring Genes: Virtual Genetic Medicines Day

GlobeNewswire May 23, 2023

Verve Therapeutics Announces Pipeline Progress and Expansion and Reports First Quarter 2023 Financial Results

GlobeNewswire May 15, 2023

Verve Therapeutics to Participate in the RBC Capital Markets 2023 Global Healthcare Conference

GlobeNewswire May 9, 2023

Verve Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day

GlobeNewswire March 27, 2023

Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates

GlobeNewswire March 3, 2023